Clinical Trials Logo

Kidney Diseases clinical trials

View clinical trials related to Kidney Diseases.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05790109 Terminated - Liver Diseases Clinical Trials

Operator and Patient Acceptance of Radiofrequency Cautery of the Biopsy Track During Percutaneous Liver, Kidney or Spleen Biopsy Procedures.

Start date: May 23, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to assess the physician and patient experience of radio frequency (RF) track cautery in patients undergoing needle biopsy of the liver, kidney, or spleen who have one or more risk factors for biopsy-related bleeding. RF track cautery involves inserting a bipolar electrode through the same introducer needle used for the biopsy, and heating the tissues along the path of the biopsy needle to prevent bleeding. This study primarily aims to assess the operator and patient experience during the use of track cautery. Secondary aims are to assess the technical success rate and procedure adverse events. Participants who enroll in the study will undergo track cautery as part of their clinically indicated liver, kidney, or spleen biopsy. After the procedure, they will fill out a brief survey asking about their experience during the procedure. Physician operators who perform track cautery as part of the study will also fill out a survey after each procedure asking about their experience using this technique.

NCT ID: NCT05747053 Terminated - Kidney Diseases Clinical Trials

Personalization of Immunosuppressive Treatment for Organ Transplant Recipients

STAART
Start date: October 1, 2020
Phase:
Study type: Observational

Long-term graft failure rates continue to be unacceptably high despite the development of immunosuppressive drugs, underscoring the unmet need for robust prognostic biomarkers of allograft injury and failure. While rates of acute rejection (AR) continue to decrease, it remains the strongest predictor of long-term allograft survival, and so having a better understanding of factors predicting AR may contribute to more individualized patient care. Selecting optimum immunosuppressive dosage is another factor in personalizing kidney care. This project will study two areas of individualized kidney care: 1) assessing rejection by surveillance testing utilizing AlloSure, 2) developing an algorithm to select optimum immunosuppressive medication dosage.

NCT ID: NCT04950114 Terminated - Kidney Diseases Clinical Trials

An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

Start date: July 27, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label Phase 2 study evaluating the long term safety and tolerability of GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD)

NCT ID: NCT04626427 Terminated - Clinical trials for Chronic Kidney Diseases

The WavelinQ™ Arterio-Venous Endovascular Fistula: A Global, Post-Market Investigation

WAVE-Global
Start date: December 22, 2020
Phase: N/A
Study type: Interventional

This is a global, multi-center, prospective, post-market, confirmatory, interventional, non-randomized, single-arm clinical investigation evaluating arteriovenous fistula (AVF) creation by means of the WavelinQ™ EndoAVF System in patients who require a vascular access for hemodialysis (HD).

NCT ID: NCT04387448 Terminated - Diabetes Mellitus Clinical Trials

A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

Start date: July 28, 2020
Phase: Phase 2
Study type: Interventional

This is a phase 2a study evaluating the safety and tolerability of multiple ascending doses of GFB-887 in patients with diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD).

NCT ID: NCT03321604 Terminated - Clinical trials for End Stage Renal Disease

Kidney Information Network for Disease Research and Education

KINDRED
Start date: January 1, 2018
Phase:
Study type: Observational [Patient Registry]

In this study, Investigators will conduct a prospective cohort study of dialysis patients by collecting research-quality information on patient characteristics, comorbid diseases and laboratory markers used in routine practice, as well as novel biochemical markers and genetic data. Investigators will utilize data from the cohort to test the independent relationship between biochemical and genetic markers and Fabry disease and other rare diseases.

NCT ID: NCT03160729 Terminated - Clinical trials for Postoperative Complications

High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Nephrectomy

DEX-NEF
Start date: April 24, 2017
Phase: Phase 4
Study type: Interventional

The aim of this study is to investigate the effect of a single preoperative high-dose steroid injection on complications in the immediate postoperative phase after open kidney surgery (kidney resection, heminephrectomy, nephrectomy). Primary outcome is complications in the post anaesthesia care unit (PACU). Secondary outcomes are organospecific complications in the post anaesthesia phase, pain and nausea the first 5 days, seroma and wound infection the first 14 days and readmissions the first 30 days after surgery. The investigators hypothesize that the frequency of transfer to the PACU and organospecific complications will be lower among patients receiving high dose dexamethasone. The investigators hypothesize, that there will be no difference in wound infections, seroma or readmissions.

NCT ID: NCT03063242 Terminated - Kidney Diseases Clinical Trials

Sargramostim for Myeloid Dendritic Cell Deficiency

Start date: February 23, 2017
Phase: Phase 2
Study type: Interventional

The study will determine whether administration of sargramostim will improve myeloid dendritic cell deficiency in various study groups, including healthy subjects and patients with chronic kidney disease, including those with kidney transplants.

NCT ID: NCT03029351 Terminated - Type2 Diabetes Clinical Trials

GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

1981
Start date: January 10, 2017
Phase: Phase 4
Study type: Interventional

This is a prospective study to evaluate effect of Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.

NCT ID: NCT02647255 Terminated - Kidney Diseases Clinical Trials

Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy

RESCUE
Start date: March 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Crescentic IgA nephropathy (CreIgAN) has a poor prognosis despite aggressive immunosuppressive therapy. The efficacy of plasma exchange (PE) in CreIgAN is not well defined. This study will evaluate the efficacy and safety of plasma exchange as adjunctive therapy for severe crescentic IgA nephropathy compared to pulse methylprednisolone on a background of oral prednisolone and cyclophosphamide in prevent kidney failure.